As of 2026-06-16, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -6.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,469.68 mil USD. RARE's TTM EBITDA according to its financial statements is -527.33 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 14.7x | 14.1x |
| Forward P/E multiples | 16.8x - 20.9x | 19.8x |
| Fair Price | (99.80) - (88.55) | (100.60) |
| Upside | -493.2% - -448.9% | -496.4% |
| Date | EV/EBITDA |
| 2026-06-12 | -6.39 |
| 2026-06-11 | -6.32 |
| 2026-06-10 | -6.13 |
| 2026-06-09 | -6.10 |
| 2026-06-08 | -5.87 |
| 2026-06-05 | -5.93 |
| 2026-06-04 | -6.19 |
| 2026-06-03 | -6.02 |
| 2026-06-02 | -5.91 |
| 2026-06-01 | -6.11 |
| 2026-05-29 | -6.31 |
| 2026-05-28 | -6.18 |
| 2026-05-27 | -6.21 |
| 2026-05-26 | -6.16 |
| 2026-05-22 | -6.21 |
| 2026-05-21 | -6.27 |
| 2026-05-20 | -6.20 |
| 2026-05-19 | -6.03 |
| 2026-05-18 | -6.36 |
| 2026-05-15 | -6.51 |
| 2026-05-14 | -6.66 |
| 2026-05-13 | -6.78 |
| 2026-05-12 | -6.85 |
| 2026-05-11 | -6.75 |
| 2026-05-08 | -6.72 |
| 2026-05-07 | -6.72 |
| 2026-05-06 | -6.68 |
| 2026-05-05 | -6.51 |
| 2026-05-04 | -6.47 |
| 2026-05-01 | -6.47 |
| 2026-04-30 | -6.45 |
| 2026-04-29 | -6.36 |
| 2026-04-28 | -6.42 |
| 2026-04-27 | -6.32 |
| 2026-04-24 | -6.34 |
| 2026-04-23 | -6.37 |
| 2026-04-22 | -6.44 |
| 2026-04-21 | -6.34 |
| 2026-04-20 | -6.52 |
| 2026-04-17 | -6.47 |
| 2026-04-16 | -6.42 |
| 2026-04-15 | -6.54 |
| 2026-04-14 | -6.43 |
| 2026-04-13 | -6.25 |
| 2026-04-10 | -6.19 |
| 2026-04-09 | -6.31 |
| 2026-04-08 | -6.16 |
| 2026-04-07 | -6.16 |
| 2026-04-06 | -6.11 |
| 2026-04-02 | -6.03 |